Form 4 Filing for AMICUS THERAPEUTICS, INC.

On April 27, 2026, Michael Aaron Kelly, a director at AMICUS THERAPEUTICS, INC. (FOLD), reported the disposition of 72,468 shares of Common Stock at a price of $14.50 per share. This transaction was part of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. In addition, all of Kelly's stock options were cancelled and converted into the right to receive a cash payment. These options, totaling 199,947 shares, were vested in full prior to or in connection with the merger. The cash payment was calculated based on the difference between $14.50 and the exercise price of each option. Following these transactions, Kelly holds no shares or options directly.